The Relative Strength (RS) Rating for Amedisys headed into a higher percentile Tuesday, as it got a lift from 65 to 73.
IBD's unique RS Rating measures market leadership by showing how a stock's price action over the last 52 weeks measures up against that of the other stocks in our database.
Over 100 years of market history shows that the best stocks tend to have an RS Rating of over 80 as they launch their largest price moves. See if Amedisys can continue to rebound and hit that benchmark.
Can You Really Time The Stock Market?
Amedisys is working on a consolidation with a 98.95 entry. See if the stock can clear the breakout price in volume at least 40% higher than normal.
The company posted 2% earnings growth in the latest quarterly report, while sales growth came in at 5%.
Amedisys holds the No. 8 rank among its peers in the Medical-Outpatient/Home Care industry group. Encompass Health, Pediatrix Medical and AdaptHealth are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
